Comment from Connected Health Initiative

Summary: The Connected Health Initiative (CHI) supports the FDA's draft guidance on AI for drug and biological products, particularly its risk-based approach and total product lifecycle perspective. They suggest prioritizing performance testing over training data transparency and urge the FDA to align its policies with existing CDRH guidance and the organization's own health AI principles.